

## FULBRIGHT &amp; JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

1301 MCKINNEY, SUITE 5100  
HOUSTON, TEXAS 77010-3095HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
LONDON  
HONG KONGTELEPHONE: 713/651-5181  
FACSIMILE: 713/651-5246THOMAS D. PAUL  
PARTNERINTERNET ADDRESS:  
tpaul@fulbright.com

DIRECT DIAL: 713/651-5325

## FACSIMILE COVER SHEET

PLEASE TRANSMIT THE FOLLOWING PAGES TO:

NAME: Examiner HinesCOMPANY/FIRM  
(LOCATION): PTOFACSIMILE 703-308-4242

VOICE PHONE: \_\_\_\_\_

From: <u>Thomas D. Paul</u>	Phone No.: <u>713-651-5325</u>	Number of Pages Sent: (Including Cover Sheet) <u>22</u>
Date: <u>November 17, 1999</u>	User No.: <u>TP4624</u>	Flr: <u>42</u>
	Matter No.: <u>Q9507111</u>	

Return Transmitted Fax To: H. Nannette GarciaRe: Musser et al. Serial No. 08/160,965

REMARKS: PLEASE DELIVER TO THE DESK OF EXAMINER HINES.

RECEIVED  
NOV 17 1999  
GROUP 1000

If you experience problems with this transmission or have questions, please call 713-651-5273.

**CONFIDENTIALITY NOTICE:** Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense. Thank you.

FOR RECEPTIONISTS ONLY

DATE/TIME RECEPTIONIST REC: \_\_\_\_\_ ☐ A.M. ☐ P.M. RECEIVED BY: \_\_\_\_\_

FOR PRINT COMMUNICATIONS ONLY

COMPLETION TIME: \_\_\_\_\_ ☐ A.M. ☐ P.M. RECEIVED BY: \_\_\_\_\_

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NO.: 08/160,965

§

DOCKET: D-5789

FILING DATE: 12/02/93

§

APPLICANT: Musser, et al.

§

EXAMINER: S. Loring

TITLE: Vaccines Containing Cysteine  
Protease and Methods to  
Protect Against Group A  
Streptococci

§

§

§

§

§

§

§

§

ART UNIT 1641

RECEIVED  
NOV 17 1999  
GROUP 1800Commissioner of Patents and Trademarks  
Washington, D.C. 20231RESPONSE TO OFFICE ACTION OF APRIL 13, 1998  
AMENDMENTS AND REMARKS

Dear Sir:

Applicants submit these remarks in response to the Office Action dated April 13, 1998 in the above-captioned application. Applicants request reconsideration of the application in view of the remarks that follow.

## AMENDMENTS

Please amend the specification as follows:

On page 5, line 9, change "Figure 2 shows" to --Figures 2A-2B show--.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 10/13/98

Ross E. Davidson



Signature

10/13/98

Date

On page 6, line 7, change "Figure 5 shows" to --Figur s 5A-5C show--.

ε<sup>1</sup> On page 6, line 8, following "prot ins.", please ins rt -- Figure 5A shows VN cleavage by speB with time. Figure 5B shows FN cleavage by speB with time. Figure 5C shows LN cleavage by speB with time.--

On page 6, line 9, please change "Figure 6 shows" to --Figures 6A-6B show--.

ε<sup>2</sup> On page 6, line 10, following "cultures.", please insert -- Figure 6A shows gels of the proteins pre and post cleavage. Figure 6B shows tissue structure pre and post cleavage.--

On page 8, line 11, please delete "claim 5".

### REMARKS

Applicants submit the following remarks in response. Applicants have amended the specification as suggested by the Examiner.

In regard to the outstanding rejections, Applicants respond as follows:

#### **35 U.S.C. § 112**

Claims 1 and 2 are rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to point out and distinctly claim the subject matter which Applicants regard as the invention. Applicants respectfully assert that Claims 1 and 2 are not indefinite.